The Team
![Albert Palomer, PhD CEO](https://endolipid.com/wp-content/uploads/2021/11/Albert_palomer.png)
Albert Palomer,
PhD CEO
Senior Executive and Development Consultant / Former CEO ABAC Therapeutics and Head of Med Chemistry at Ferrer and Menarini / Boards member and advisor to start-ups in Spain, Belgium, and S Africa / Co-developer of the NSAID analgesic Enantyum® and the quinolone antibiotic Ozanex®.
![Ferrer - ABAC](https://endolipid.com/wp-content/uploads/2023/05/logo_ferrer_abac.png)
![David M Selva, PhD CSO](https://endolipid.com/wp-content/uploads/2021/11/david_m_selva_v2.png)
David M. Selva,
PhD CSO
Board Member and Scientific Leader / Worldwide expert and KOL on SHBG / Extensive experience on molecular mechanisms regulating SHBG and its role in human disease development / More than 30 papers published in top international journals.
![Vall d'Hebron Institut de Recerca](https://endolipid.com/wp-content/uploads/2023/05/logo_vall_debron_recerca.png)
![Rafael Simó, MD, Prof CMO](https://endolipid.com/wp-content/uploads/2021/11/rafael_simo.png)
Rafael Simó, MD, Prof
CMO
Head of Endocrinology and Nutrition Department / Deputy Director of Clinical Research at Campus Vall d’Hebron / Professor of Medicine & Endocrinology. Universitat Autònoma de Barcelona / President of the European Association for the Study of Diabetes- Eye Complications.
![Vall d'Hebron Institut de Recerca](https://endolipid.com/wp-content/uploads/2023/05/logo_vall_dhebron_recerca_2.png)
![Agustí Soler CFO](https://endolipid.com/wp-content/uploads/2023/05/agusti_soler.png)
Agustí Soler,
CFO
Financial officer in several start-up companies Cority, Aortix, Endolipid, etc Finance and tax consultant at the FI-Ready Group of Companies.
![Fiboost](https://endolipid.com/wp-content/uploads/2023/05/logo_fiboost.png)
Anna Alvarez, PhD
In vivo models
Laura Brianso, PhD
In vitro models
Pablo Gabriel,
PhD Student
Lorena Ramos,
Lab Technician
Endolipid Therapeutics
Who are we?
![Science meets Business](https://endolipid.com/wp-content/uploads/2021/11/ico_science_01.png)
![Vall d'Hebron Recerca](https://endolipid.com/wp-content/uploads/2021/12/ico_vall_dhebron.png)
![Genesis Ventures](https://endolipid.com/wp-content/uploads/2021/11/ico_genesis.png)
![Nanovex](https://endolipid.com/wp-content/uploads/2023/05/ico_nanovex.png)
What do we do?
How do we do it?
![Capital Cell - Ministerio de Ciencia e Innovación. Granted 2023](https://endolipid.com/wp-content/uploads/2023/09/icono_capital_cell_ministerio.png)
Pathologies Derived from Fat Accumulation
Increased ectopic fat accumulation:
![](https://endolipid.com/wp-content/uploads/2021/11/photo_higado.png)
Fatty liver and NASH
- Liver fat accumulation, fibrosis and inflammation leading to cirrhosis.
- Silent disease, low awareness and poor diagnosis.
- Co-morbidities obesity, diabetes, hyperlipidemia and hypertension.
![Cellulite - Subcutaneous fat](https://endolipid.com/wp-content/uploads/2021/11/photo_cellulite2.png)
Cellulite
- Undesirable fat deposits in subcutaneous adipocyte.
- Socially subterfuge disease affecting +80% pot-puberal females.
- Scarce science-based innovation in the last decade.
Endolipid proposed strategy:
Sex Hormone Binding Globulin (SHBG)
Mimicking SHBG, an innovative new strategy to reduce ectopic fat accumulation.
![SHBG](https://endolipid.com/wp-content/uploads/2021/11/SHBG_grey.png)
Sex Hormone-Binding Globulin
- Plasma glycoprotein
- Produced by the liver and secreted Into the blood.
- Binds sex steroids.
- Low plasma SHBG levels related to subjects with obesity, fatty liver, type 2 diabetes and PCOS.
(1) Lipolysis: Sáez-López et al 2020 J Nutr Biochem.
(2) Lipogenesis: Sáez-López et al 2015 and 2017 Endocrinology.
(3) Lipogenesis, Inflammation: Sáez-López et al 2019 JCEM),
(4) Fibrosis: Selva DM et al unpublished.
(5) Inflammation: Yamazaki H et al 2018 Mediators Inflamm.
The ENDOLIPID Technology.
SHBG-mimic Peptides
Peptides mimicking SHBG are useful to treat fatty liver diseases and reduce cellulite.
Therapeutic and dermocosmetic applications.
![SHBG-mimic: EDL Technology® EDL3D peptide: Innovation in dermocosmetics. EDL6D peptide: Innovation in NASH therapeutics](https://endolipid.com/wp-content/uploads/2023/05/tecnology_mobile_v3.png)
EDL6D is a new peptide that restores
SHBG functions and reduces the main causes of NASH
![EDL6D is a new peptide that restores SHBG functions and reduces the main causes of NASH](https://endolipid.com/wp-content/uploads/2023/05/endolipid_technology_v3.webp)
Peptide EDL6D in vivo Validation
EDL6D is aligned with next generation treatments reducing main causes of NASH
![Chart: Steatosis, Fibrosis](https://endolipid.com/wp-content/uploads/2023/09/peptido_vivo_01_v2.webp)
![](https://endolipid.com/wp-content/uploads/2021/11/bg_productos-scaled.jpg)
Endolipid (EDL) Peptide Products
Mimicking SHBG, an innovative approach to NASH and cellulite thin pipelines.
Two peptides EDL6D (NASH) is in preclínical development and
EDL81 (Cellulite) is in co-development
![ADL6D Nash](https://endolipid.com/wp-content/uploads/2021/11/bote_pills.png)
EDL6D – NASH.
![EDL81 Cellulite](https://endolipid.com/wp-content/uploads/2023/05/EDL81.webp)
EDL81 – Cellulite.
![Nanovex](https://endolipid.com/wp-content/uploads/2023/05/nanovex_white.png)